North America Therapeutic Vaccines Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The North America therapeutic vaccines market is projected to grow significantly, reaching approximately USD 1,360,744.52 thousand by 2031, up from USD 565,764.46 thousand in 2024, reflecting a compound annual growth rate (CAGR) of 13.4% from 2024 to 2031.

Executive Summary and Market Analysis

The therapeutic vaccines market in North America is divided into three main regions: the United States, Canada, and Mexico. The U.S. is expected to be a key driver of market growth due to several factors, including the rising incidence of cancer, increased investment in research and development, and a notable rise in product launches. Additionally, strategic initiatives such as the introduction of new products, regulatory approvals, partnerships, and acquisitions are further enhancing the growth of the therapeutic vaccine market in this region.

Market Segmentation Analysis

The therapeutic vaccines market can be analyzed through various segments, including product type, technology, and end user.

By Product: The market is categorized into cancer vaccines, infectious disease vaccines, and others, with cancer vaccines holding the largest market share in 2024.
By Technology: The market is divided into allogenic and autologous vaccines, where allogenic vaccines are expected to dominate the market share in 2024.
By End User: The end-user segment includes hospitals, clinics, and others, with hospitals accounting for the largest share in 2024.

Market Outlook

The prevalence of chronic conditions such as cancer, neurological disorders, and autoimmune diseases is on the rise globally, driven by factors like aging populations, lifestyle changes, and environmental influences. According to the World Health Organization (WHO), noncommunicable diseases lead to 41 million deaths annually, representing 74% of total mortality. In 2022, around 20 million new cancer cases were diagnosed, with approximately 9.7 million deaths attributed to the disease. Furthermore, a study published in The Lancet Neurology in April 2024 indicated that over 3 billion people, or 43% of the global population, were living with neurological conditions as of 2021. Autoimmune diseases affect 5-10% of the population in industrialized nations, impacting around 50 million Americans. The WHO also reported that over 1.8 million people worldwide suffered from multiple sclerosis as of August 2023.

These alarming statistics underscore the urgent need for innovative therapeutic solutions. Therapeutic vaccines are designed to treat existing diseases rather than prevent them, aiming to activate the immune system to target specific diseases. For instance, the Sipuleucel-T (Provenge) vaccine has shown promise in improving survival rates for prostate cancer patients. As the demand for innovative treatments for chronic diseases rises, therapeutic vaccines are positioned to provide new avenues for long-term disease management and enhanced patient outcomes.

Country Insights

The North American therapeutic vaccines market is primarily composed of the U.S., Canada, and Mexico, with the U.S. holding the largest market share in 2024. The growth of the therapeutic vaccines market in the U.S. is fueled by the increasing prevalence of chronic diseases, including cancer and infectious diseases. The American Cancer Society reported that in 2022, over 1.9 million new cancer cases were diagnosed, resulting in approximately 610,000 deaths. In 2024, the number of cancer diagnoses in the U.S. is expected to reach 2 million. This surge in cancer cases is driving the demand for innovative treatment options, with therapeutic vaccines offering promising alternatives to traditional therapies. Provenge, the first FDA-approved therapeutic cancer vaccine for prostate cancer, exemplifies the potential of immunotherapies to extend patient survival. The rising incidence of cancer is prompting increased investment in research and development and fostering collaborations between companies and academic institutions.

Company Profiles

Key players in the therapeutic vaccines market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon, among others. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their product offerings and increase their market presence.

Product Code: BMIRE00032090

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. North America Therapeutic Vaccines Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Rising Prevalence of Chronic Conditions
- 4.1.2 Increasing Investments and Funding for Vaccine Development
4.2 Market Restraints
- 4.2.1 Regulatory Challenges
4.3 Market Opportunities
- 4.3.1 Extending Product Pipeline
4.4 Future Trends
- 4.4.1 Advancements in Vaccine Technology
4.5 Impact of Drivers and Restraints:

5. Therapeutic Vaccines Market - North America Market Analysis

5.1 North America Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
5.2 North America Therapeutic Vaccines Market Forecast Analysis

6. North America Therapeutic Vaccines Market Analysis - by Product

6.1 Cancer Vaccine
- 6.1.1 Overview
- 6.1.2 Cancer Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.2 Infectious Disease Vaccine
- 6.2.1 Overview
- 6.2.2 infectious Disease Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.3 Others
- 6.3.1 Overview
- 6.3.2 Others: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

7. North America Therapeutic Vaccines Market Analysis - by Technology

7.1 Allogenic Vaccine
- 7.1.1 Overview
- 7.1.2 Allogenic Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
7.2 Autologous Vaccine
- 7.2.1 Overview
- 7.2.2 Autologous Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

8. North America Therapeutic Vaccines Market Analysis - by End User

8.1 Hospitals
- 8.1.1 Overview
- 8.1.2 Hospitals: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.2 Clinics
- 8.2.1 Overview
- 8.2.2 Clinics: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

9. North America Therapeutic Vaccines Market - Country Analysis

9.1 North America
- 9.1.1 North America Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.1 North America Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.2 United States: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.2.1 United States: North America Therapeutic Vaccines Market Share - by Product
    - 9.1.1.2.2 United States: North America Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.2.3 United States: North America Therapeutic Vaccines Market Share - by End User
  - 9.1.1.3 Canada: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.3.1 Canada: North America Therapeutic Vaccines Market Share - by Product
    - 9.1.1.3.2 Canada: North America Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.3.3 Canada: North America Therapeutic Vaccines Market Share - by End User
  - 9.1.1.4 Mexico: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.4.1 Mexico: North America Therapeutic Vaccines Market Share - by Product
    - 9.1.1.4.2 Mexico: North America Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.4.3 Mexico: North America Therapeutic Vaccines Market Share - by End User

10. Therapeutic Vaccines Market - Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Therapeutic Vaccines Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Dendreon
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 BioNTech SE
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Serum Institute of India Pvt. Ltd
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Merck & Co Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Amgen Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 ISA Pharmaceuticals BV
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 INOVIO Pharmaceuticals Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Transgene SA
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 THERAVECTYS SA
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 CureVac SE
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms